食管胃癌的靶向药物治疗进展

被引:5
作者
曹怀刚
王子安
机构
[1] 蚌埠医学院第一附属医院肿瘤内科
关键词
食管癌; 胃癌; 靶向药物; 治疗进展;
D O I
暂无
中图分类号
R735 [消化系肿瘤];
学科分类号
摘要
<正>尽管对食管胃癌的治疗进行了不断的研究,但食管胃癌患者长期存活的预后仍然很差。局部晚期食管癌胃癌采用单纯外科手术治疗的5年生存率只有20%~25%[1];行综合治疗即行术前化疗放疗或术后放疗化疗的5年生存率也仅能达到30%~35%[2]。在有远处转移的情况下,化疗成为治疗的主要手段,但治疗的客观反应率(objective response rates,ORR)仅为20%~40%,中位总生存期(overall survivals,OS)为8~10个月[3]。近来的研究行第3种化疗药加入两药方案,虽然在生存期上稍有提高,但具有明显的不良反应[4,5]。这些潜在的毒性限制了3药联合化疗在那些老年患者和一般情况较差的患者中
引用
收藏
页码:536 / 539
页数:4
相关论文
共 8 条
[1]  
Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity[J] . Howard Safran,Mohan Suntharalingam,Thomas Dipetrillo,Thomas Ng,L. Austin Doyle,Mark Krasna,Angela Plette,Devon Evans,Harold Wanebo,Paul Akerman,Jeremy Spector,Nancy Kennedy,Teresa Kennedy.International Journal of Radiation Oncology, Biology, Physics . 2008 (2)
[2]  
Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma[J] . Howard Safran,Thomas DiPetrillo,Paul Akerman,Thomas Ng,Devon Evans,Margaret Steinhoff,David Benton,John Purviance,Lisa Goldstein,Umadevi Tantravahi,Teresa Kennedy.International Journal of Radiation Oncology, Biology, Physics . 2007 (2)
[3]  
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial[J] . George D Demetri,Allan T van Oosterom,Christopher R Garrett,Martin E Blackstein,Manisha H Shah,Jaap Verweij,Grant McArthur,Ian R Judson,Michael C Heinrich,Jeffrey A Morgan,Jayesh Desai,Christopher D Fletcher,Suzanne George,Carlo L Bello,Xin Huang,Charles M Baum,Paolo G Casali.The Lancet . 2006 (9544)
[4]  
Epidermal growth factor receptorinhibitor-associated cutaneous toxicities:an evolving paradigmin clini-cal managemen〔tJ〕 .2 Lynch Jr TJ,Kim ES,Eaby B,et al. Oncologist . 2007
[5]  
ABX-EGF,a fully humananti-epidermal growth factor receptor (EGFR)monoclonal antibody (mAb)inpatients with advanced cancer:phase 1 clinical results〔J〕 .2 Figlin R,Belldegrun A,Crawford J,et al. Proc Am Soc Clin Oncol . 2002
[6]  
S0413:aphaseSWOG study of GW572016 (lapatinib)as first line therapy inpatients (ptwith advanced or metastatic gastric cancer〔J〕 .2 Iqbal S,Goldman B,Lenz H,Fenoglio-Preiser C,Blanke C. J Clin On-col . 2007
[7]  
Efficacy results from the To-GA trial phaseⅢstudy of trastuzumab added to standard chemother-apy (CT)in firsline human epidermal growth factor receptor 2 (HER2)-positive advancegastric cancer (GC)〔J〕 .2 Van Cutsem E,Kang Y,Chung H,et al. J Clin Oncol . 2009
[8]  
Phase II trial of preoperative bevacizum-ab (Bev),irinotecan (I) cisplatin (C),and radiation (RT)in e-sophageal adenocarcinoma:preliminary safety analysis〔J〕 .2 IlsonD,BainsM,RizkN,et al. J Clin On-col . 2009